Table 3.

Selected examples of studies that have either verified, or detracted from the importance of transporter polymorphisms on drug treatment after in vitro or in vivo validation

Transporter	Drug	In vitro or in vivo verification of polymorphic effects	Ref.	Clinical verification of inter-individual variability	Ref.
ABCB1
	Fexofenadine	Increased transport with 893Ser Increased transport with 893Thr	[98]	Decreased AUC in patients with 2677TT and 2677AA genotypes	[30, 99]
	Docetaxel	Decreased expression of ABCB1 in survival unchanged.	[70, 71]	Docetaxel AUC and overall liver with 3435TT genotype	[100–102]
		Docetaxel is transported by ABCB1	[103]
ABCG2
	Topotecan	Increased accumulation of drug in cells transfected with 421A (Q141K)	[104]	Increased bioavailability in heterozygous C421A patients	[104]
	Imatinib	Increased accumulation of drug in cells transfected with 421A (Q141K)	[105]	No significant difference in AUC or Cmax in heterozygous C421 patients	[105]
ABCC1
	N/A	None to date
ABCC2
	N/A	None to date
OATP1B1
	Pravastatin	Reduced membrane expression of OATP1B1*5 variant	[45]	Increased AUC in OATP1B1*5	[94, 106]
OATP1B3	Leuprolide and goserelin	Reduced transport of testosterone with the 334G/699A haplotype	[24]	Increased progression-free survival in patients with 334G/699A haplotype	[97]